As a potential treatment of COVID-19: Montelukast
No Thumbnail Available
Files
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.